Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.73. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals.
| REGN | VTIP | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | — |
52-Week High | $852.03 | $50.75 |
52-Week Low | $555.51 | $49.39 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
VTIP trades at $49.75 with minimal daily movement (+0.04%). Technical indicators show a bearish bias with moving averages signaling caution, while oscillators remain neutral. The ETF focuses on short-term inflation-protected securities, offering minimal interest-rate sensitivity. Recent institutional activity includes 55 North Private Wealth increasing its position by 12.2% in Q2 2026.
Outlook remains cautious given bearish technical signals and persistent inflation concerns. The fund provides inflation hedging with reduced rate risk, but limited growth potential and competitive TIPS alternatives present challenges. Investors seeking short-duration inflation protection may find value, though overall market sentiment suggests tempered expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
